Larimar Therapeutics Inc (LRMR) Stock Price, Quote & News

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 844 511 9056

Website: www.larimartx.com

Address:

Three Bala Plaza East, Suite 506, Bala Cynwyd, United States

maurizio58 Apr. 7 at 3:52 PM

$LRMR Calm and quiet, never count your chickens before they're hatched.

0 · Reply

twycgnb Apr. 7 at 2:30 PM

$LRMR I guess all that spike over five did was get shorts attention to drive it back down again ... Womp womp

0 · Reply

DiviDiVa20 Apr. 7 at 2:44 AM

$LRMR

0 · Reply

maurizio58 Apr. 6 at 4:29 PM

$LRMR Good

0 · Reply

nopennys Apr. 6 at 10:41 AM

$LRMR

0 · Reply

twycgnb Apr. 1 at 2:00 PM

$LRMR - it's time for the "somebody knows something" comment :)

0 · Reply

Nescu Mar. 31 at 4:38 PM

$LRMR Time to change direction, given that tomorrow we enter Q2, and topline data results announce to be transformative. It's time to cover and buy.

0 · Reply

kenny91655 Mar. 30 at 7:14 PM

$LRMR Buying this and NVDA and JEPI

0 · Reply

Nescu Mar. 30 at 3:57 PM

$LRMR Oversubscribed offering down 15%. Congratulations and thank you for your funds!

1 · Reply

twycgnb Mar. 30 at 3:26 PM

$LRMR ...Uhh... The offering is at $5 here people .. wrong direction

0 · Reply

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 4:05 PM EST - 4 weeks ago

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Feb 25, 2026, 8:59 PM EST - 5 weeks ago

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Feb 25, 2026, 4:01 PM EST - 5 weeks ago

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Feb 25, 2026, 2:30 PM EST - 5 weeks ago

Laminar Therapeutics Stock Is Popping Today: What's Going On?

Feb 24, 2026, 12:12 PM EST - 6 weeks ago

Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation

Feb 24, 2026, 7:00 AM EST - 6 weeks ago

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Dec 18, 2025, 8:00 AM EST - 3 months ago

Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 6:45 AM EST - 4 months ago

Top 3 Health Care Stocks That May Rocket Higher In December

ORIC PRGO

Nov 5, 2025, 7:00 AM EST - 5 months ago

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

Oct 16, 2025, 4:44 AM EDT - 6 months ago

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

Oct 16, 2025, 4:40 AM EDT - 6 months ago

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Oct 15, 2025, 9:30 PM EDT - 6 months ago

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR

Sep 29, 2025, 11:20 AM EDT - 6 months ago

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Sep 29, 2025, 7:00 AM EDT - 6 months ago

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia

Sep 28, 2025, 5:00 PM EDT - 6 months ago

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Aug 14, 2025, 7:00 AM EDT - 8 months ago

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 4:15 PM EDT - 8 months ago

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jul 29, 2025, 11:50 PM EDT - 8 months ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

Jul 29, 2025, 4:01 PM EDT - 8 months ago

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Jul 8, 2025, 7:00 AM EDT - 9 months ago

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

Jun 23, 2025, 7:00 AM EDT - 10 months ago

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Jun 20, 2025, 4:05 PM EDT - 10 months ago

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:05 PM EST - 1 year ago

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Jan 23, 2025, 4:05 PM EST - 1 year ago

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Dec 17, 2024, 1:39 PM EST - 1 year ago

What's Going On With Larimar Therapeutics Stock On Tuesday?

Dec 16, 2024, 12:17 PM EST - 1 year ago

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

Dec 16, 2024, 7:00 AM EST - 1 year ago

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 16, 2024, 2:59 PM EDT - 1 year ago

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

May 30, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

May 20, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

May 9, 2024, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Mar 11, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

Mar 6, 2024, 4:05 PM EST - 2 years ago

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 14, 2024, 6:15 AM EST - 2 years ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Feb 12, 2024, 7:00 AM EST - 2 years ago

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Nov 14, 2023, 7:00 AM EST - 2 years ago

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Oct 3, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Jul 25, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

Jul 17, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

Jun 21, 2023, 4:05 PM EDT - 3 years ago

Larimar Therapeutics Set to Join Russell 3000® Index

maurizio58 Apr. 7 at 3:52 PM

$LRMR Calm and quiet, never count your chickens before they're hatched.

0 · Reply

twycgnb Apr. 7 at 2:30 PM

$LRMR I guess all that spike over five did was get shorts attention to drive it back down again ... Womp womp

0 · Reply

DiviDiVa20 Apr. 7 at 2:44 AM

$LRMR

0 · Reply

maurizio58 Apr. 6 at 4:29 PM

$LRMR Good

0 · Reply

nopennys Apr. 6 at 10:41 AM

$LRMR

0 · Reply

twycgnb Apr. 1 at 2:00 PM

$LRMR - it's time for the "somebody knows something" comment :)

0 · Reply

Nescu Mar. 31 at 4:38 PM

$LRMR Time to change direction, given that tomorrow we enter Q2, and topline data results announce to be transformative. It's time to cover and buy.

0 · Reply

kenny91655 Mar. 30 at 7:14 PM

$LRMR Buying this and NVDA and JEPI

0 · Reply

Nescu Mar. 30 at 3:57 PM

$LRMR Oversubscribed offering down 15%. Congratulations and thank you for your funds!

1 · Reply

twycgnb Mar. 30 at 3:26 PM

$LRMR ...Uhh... The offering is at $5 here people .. wrong direction

0 · Reply

Nescu Mar. 30 at 2:09 PM

$LRMR Just sell your shares, and we add to gainers. No need to hold on to your losses.

0 · Reply

Nescu Mar. 30 at 1:56 PM

$LRMR Breakthrough Therapy Joke! In two days we enter Q2, let's see how top is the topline data! SHORT!

0 · Reply

Nescu Mar. 30 at 1:35 PM

$LRMR Our shorts pay off very well so far. Thank you MR Trump! Let's add to our gains!

0 · Reply

Core366 Mar. 28 at 9:17 PM

$LRMR Desperate short pfffft.

0 · Reply

OfficialStocktwitsUser Mar. 27 at 9:49 PM

$LRMR RSI: 27.62, MACD: 0.1108 Vol: 0.46, MA20: 4.91, MA50: 4.09 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Nescu Mar. 27 at 6:43 PM

$LRMR Things go according to the plan, adding on gains. There is no hope for turnaround until May.

0 · Reply

Nescu Mar. 27 at 2:16 PM

$LRMR A disease-modifying therapy that is unable to even maintain the price of a huge offering. Short!

0 · Reply

Nescu Mar. 26 at 7:08 PM

$LRMR Struggling to get even closer to the $5 base. It is a good time to add to shorts.

1 · Reply

BioResearcher Mar. 26 at 2:08 PM

$LRMR $20+

0 · Reply

maurizio58 Mar. 26 at 1:51 PM

$LRMR for me we are in the accumulation phase

0 · Reply

gorillasticday Mar. 26 at 12:47 PM

$LRMR claude tells me this thing is going to the fucking moon is it right?

0 · Reply

Nescu Mar. 25 at 7:21 PM

$LRMR Still 20% from the previous last week high. It finds it almost impossible to recover.

1 · Reply

Market Cap	497.60M
Revenue (ttm)	0.00
Net Income (ttm)	-165.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	374,498
Avg Vol	4,951,660
Day's Range	N/A - N/A
Shares Out	103.88M
Stochastic %K	93%
Beta	1.02
Analysts	Strong Sell
Price Target	$16.70